British medics have made an important statement about the treatment of covid with aspirin, which is included in medical protocols in many countries.
According to a large-scale study, this drug does not improve the survival of hospitalized with COVID-19 and there is no need to prescribe it if such a patient has not taken the drug for other reasons before coronavirus.
The research paper revealed that “there was no evidence that aspirin treatment reduced mortality” and “no significant difference” in the number of people that died, with 17% of people in both groups dying in hospital after 28 days.
- Brief Anger Hampers Blood Vessel Function Leading to Increased Risk of Heart Disease and Stroke – New Study
- New Blood Test Pinpoints Future Stroke Risk – Study Identifies Inflammatory Molecules as Key Biomarker
- Enceladus: A Potential Haven for Extraterrestrial Life in its Hidden Ocean Depths
- New Experiment: Dark Matter Is Not As ‘DARK’ As All We Think
- Scientists in Fear of This New Predator From Red Sea Eating Native Species in Mediterranean
It is reported that from November 2020 to March 2021, about 15,000 patients took part in the British study: 7351 received aspirin (150 mg once a day), and 7,541 people were treated without this drug.
Now doctors report that they have not been able to prove that aspirin somehow reduces the risks and protects the infected from death or the ventilator. Experts did not see a significant difference in 28-day mortality (17% in the aspirin group and 17% in the placebo group).
The data show that in patients hospitalized with Covid-19, aspirin was not associated with reductions in 28-day mortality or in the risk of progressing to invasive mechanical ventilation or death
says Peter Horby, professor of emerging infectious diseases in the Nuffield Department of Medicine at the University of Oxford, and joint chief investigator for the RECOVERY trial.
However, in those patients who took aspirin in the hospital, the length of hospital stay was slightly shorter (by 1%).
Although aspirin was associated with a small increase in the likelihood of being discharged alive this does not seem to be sufficient to justify its widespread use for patients hospitalized with Covid-19.
There has been a strong suggestion that blood clotting may be responsible for deteriorating lung function and death in patients with severe Covid-19. Aspirin is inexpensive and widely used in other diseases to reduce the risk of blood clots so it is disappointing that it did not have a major impact for these patients. This is why large randomised trials are so important – to establish which treatments work and which do not.
- Brief Anger Hampers Blood Vessel Function Leading to Increased Risk of Heart Disease and Stroke – New Study
- New Blood Test Pinpoints Future Stroke Risk – Study Identifies Inflammatory Molecules as Key Biomarker
- Enceladus: A Potential Haven for Extraterrestrial Life in its Hidden Ocean Depths
- New Experiment: Dark Matter Is Not As ‘DARK’ As All We Think
- Scientists in Fear of This New Predator From Red Sea Eating Native Species in Mediterranean
The results of the latest research paper, submitted to a leading peer-reviewed medical journal, to be published shortly on pre-print site medRxiv as cited by CNBC.
Image Credit: Getty